BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29055700)

  • 1. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreducible carboxymethyl dextran nanoparticles for tumor-targeted drug delivery.
    Thambi T; You DG; Han HS; Deepagan VG; Jeon SM; Suh YD; Choi KY; Kim K; Kwon IC; Yi GR; Lee JY; Lee DS; Park JH
    Adv Healthc Mater; 2014 Nov; 3(11):1829-38. PubMed ID: 24753360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxymethyl dextran-based hypoxia-responsive nanoparticles for doxorubicin delivery.
    Son S; Rao NV; Ko H; Shin S; Jeon J; Han HS; Nguyen VQ; Thambi T; Suh YD; Park JH
    Int J Biol Macromol; 2018 Apr; 110():399-405. PubMed ID: 29133095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored design of multifunctional and programmable pH-responsive self-assembling polypeptides as drug delivery nanocarrier for cancer therapy.
    Wang TW; Yeh CW; Kuan CH; Wang LW; Chen LH; Wu HC; Sun JS
    Acta Biomater; 2017 Aug; 58():54-66. PubMed ID: 28606810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zwitterionic nanoparticles constructed from bioreducible RAFT-ROP double head agent for shell shedding triggered intracellular drug delivery.
    Huang P; Liu J; Wang W; Zhang Y; Zhao F; Kong D; Liu J; Dong A
    Acta Biomater; 2016 Aug; 40():263-272. PubMed ID: 26607767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH and redox dual-sensitive polysaccharide nanoparticles for the efficient delivery of doxorubicin.
    Yang S; Tang Z; Zhang D; Deng M; Chen X
    Biomater Sci; 2017 Sep; 5(10):2169-2178. PubMed ID: 28914292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
    Cheng B; Gao F; Maissy E; Xu P
    Acta Biomater; 2019 Jan; 84():378-390. PubMed ID: 30528604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
    Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
    J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
    Khondee S; Chittasupho C; Tima S; Anuchapreeda S
    Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zwitterionic pH/redox nanoparticles based on dextran as drug carriers for enhancing tumor intercellular uptake of doxorubicin.
    Wu L; Zhang L; Shi G; Ni C
    Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():278-85. PubMed ID: 26838851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.
    Han HS; Thambi T; Choi KY; Son S; Ko H; Lee MC; Jo DG; Chae YS; Kang YM; Lee JY; Park JH
    Biomacromolecules; 2015 Feb; 16(2):447-56. PubMed ID: 25565417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy.
    Misra R; Sahoo SK
    Eur J Pharm Sci; 2010 Jan; 39(1-3):152-63. PubMed ID: 19961929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.
    Kutlehria S; Behl G; Patel K; Doddapaneni R; Vhora I; Chowdhury N; Bagde A; Singh M
    AAPS PharmSciTech; 2018 Feb; 19(2):792-802. PubMed ID: 29019073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
    Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
    Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
    Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
    J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-Stitched Polysaccharide Vesicles for Synergistic Cancer Therapy of Triple Antagonistic Drugs.
    Deshpande NU; Jayakannan M
    Biomacromolecules; 2017 Jan; 18(1):113-126. PubMed ID: 28064505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.